Rosiglitazone, marketing, and medical science.
Moynihan
Ray
R
University of Newcastle, Newcastle, Australia. ray.moynihan@newcastle.edu.au
D002986:Clinical Trials as Topic; D016265:Conflict of Interest; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004345:Drug Industry / Q000941:ethics*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007400:Interprofessional Relations / Q000941:ethics; D008389:Marketing of Health Services / Q000941:ethics*; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced*; D000077154:Rosiglitazone; D056737:Safety-Based Drug Withdrawals; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration / Q000941:ethics
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone